Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-02-06
2007-02-06
Schnizer, Richard (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023200, C536S023500, C536S023510, C536S023520, C530S300000, C530S350000, C435S320100, C514S054000
Reexamination Certificate
active
10234406
ABSTRACT:
A nucleic acid formulation for use in gene delivery comprising a nucleic acid and an anionic polymer is disclosed. Examples of the anionic polymer includes aniionic amino acid polymer or poly-amino acid (such as poly-L-glutamic acid, poly-D-glutamic acid, poly-L-aspartic acid, poly-D-aspartic acid), poly-acrylic acid, polynucleotides, poly galacturonic acid, and poly vinyl sulfate.
REFERENCES:
patent: 4543252 (1985-09-01), Lehrer et al.
patent: 4675381 (1987-06-01), Bichon
patent: 4976962 (1990-12-01), Bichon et al.
patent: 5439440 (1995-08-01), Hofmann
patent: 5679647 (1997-10-01), Carson et al.
patent: 5702384 (1997-12-01), Umeyama et al.
patent: 5704908 (1998-01-01), Hofmann et al.
patent: 5856435 (1999-01-01), Bazile et al.
patent: 5904936 (1999-05-01), Huille et al.
patent: 5945290 (1999-08-01), Cowsert
patent: 6040925 (2000-03-01), Vondran, Jr. et al.
patent: 6048551 (2000-04-01), Hilfinger et al.
patent: 6096335 (2000-08-01), Thierry
patent: 6271205 (2001-08-01), Ross et al.
patent: 6383811 (2002-05-01), Wolff et al.
patent: 6413941 (2002-07-01), Garnett et al.
patent: WO 94/24983 (1994-11-01), None
patent: WO 95/24929 (1995-09-01), None
patent: WO 96/21470 (1996-07-01), None
patent: WO98/19710 (1998-05-01), None
patent: WO00/03694 (2000-01-01), None
patent: WO00/30618 (2000-06-01), None
patent: WO 00/78357 (2000-12-01), None
patent: WO 00/78791 (2000-12-01), None
patent: WO01/13723 (2001-01-01), None
Trubetskoy et al (Nucl. Acids Res. 27(15): 3090-3095, Aug. 1999).
Zhang et al (Human Gene Therapy 8: 1763-1772, Oct. 1997).
1998 Promega Biological Research Products Catalog, pp. 248 and 264.
GenBank Accession No. U47119, May 10, 2004.
Yeow et al (J. Immunol. 160: 2932-2939, Mar. 1998).
GenBank Accession No. AAB59737, Jun. 19, 2002.
GenBank Accession No. AAA61621, Jan. 27, 1995.
1992 Sigma Chemical Company Catalog, pp. 1742 and 1743.
Maniatis et al (In Molecular Cloning, Cold Spring Harbor Laboratory, 1982, pp. 86-95 and 448).
Abruzzese , RV et al, Ligand-Dependent Regulation of Plasimd-Based Transgene Expression in Vivo, Human Gene Therapy 10 (1999) 1499-1507.
Aihara H et al, Gene Transfer into Muscle by Electroporation in vivo. Nature Biotech 16 (1998) 867.
Ayers, D et al, Polyacrylic acid mediated ocular delivery of ribozymes, Journal of Controlled Release, 1996, 167-175, vol. 38.
Bettan, M et al, High-Level Protein Secretion into Blood Circulation after Electric Pulse-Mediated Gene Transfer into Skeletal Muscle, Molecular Therapy, Sep. 2000, 204-210, vol. 2 No. 3.
Bourne, N et al, DNA Immunization against Experimental Genital Herpes Simplex Virus Infection, Journal of Infectious Diseases, 1996, 800-807, vol. 173.
Chuah, MKL et al, Gene Therapy for Hemophilia, Journal of Gene Medicine, Jan.-Feb. 2001, 3-20, vol. 3.
Connor, RJ et al, Identification of polyamides that enhance adenovirus-mediated gene expression in the urothelium, Gene Therapy, Jan. 2001, 41-48, vol. 8.
Davis, HL et al, Direct Gene Transfer into Skeletal Muscle In Vivo: Factors Affecting Efficiency of Transfer and Stability of Expression, Human Gene Therapy, 1993, 151-159, vol. 4.
Dekie, L et al, Poly-L-glutamic acid derivatives as vectors for gene therapy, Journal of Controlled Release, 2000, 187-202, vol. 65.
Erbacher, P et al, The reduction of the positive charges of polylysine by partial gluconoylation increases the transfection efficiency of polylysine/DNA complexes, Biochimica et Biophysica Acta, 1997, 27-36, vol. 1324.
Fewell, J et al. Expression of Factor IX in Mice and Hemophilic B Dogs Following Intramuscular Injections of PINC Forumlated Plasmid with Electroporation. Blood 96 (2000) 803A.
Fakhrai H et al, Eradication of established intracranial rat gliomas by transforming growth factor Beta antisense gene therapy, Proc. Natl. Acad. Sci., Apr. 1996, 2909-2914, vol. 93.
Goto, T et al, Highly efficient electro-gene therapy of solid tumor by using an expression plasmid for the herpes simplex virus thymidine kinase gene, PNAS, Jan. 4, 2000, 354-359, vol. 97 No. 1.
Hagstrom, J et al, Improved muscle-dervied expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter, Blood, Apr. 15, 2000, 2536-2542, vol. 95 No. 8.
Hagstrom, J et al, Complexes of non-cationic liposomes and histone H1 mediate efficient transfection of DNA without encapsulation, Biochemica et Biophysica Acta, 1996, 47-55, vol. 1284.
Hartikka, J et al, Sodium phosphate enhances plasmid DNA expression in vivo, Gene Therapy, 2000, 1-12, vol. 7.
Chao H et al Persistant Expression of Canine Factor IX in Hemophilia B Canines, Gene Therapy 6 (1999) 1695.
Herzog, R W et al, Long-term corrction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector, Nature, Jan. 1999, 56-63, vol. 5 No. 1.
Herzog, R W et al, Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus, PNAS, May 1997, 5804-5809, vol. 94.
Hoffman, S L et al, Strategt for development of a pre-erythrocyticPlasmodium falciparumDNA vaccine for human use, Vaccine, 1997, 842-845, vol. 15 No. 8.
Ichiba, Y and Kenichi Yoshikawa, Single Chain Observation on Collapse Tansition in Giant DNA Induced by Negatively-Charger Polymer, Biochemical and Biophysical Research Communications, 1998, 441-445, vol. 242.
Jaroszeski, MJ et al, In vivo antitumor effects of electrochemotherapy in a hepatoma model, Biochemica et Biophysica Acta, 1997, 15-18, vol. 1334.
Kay, M et al, In vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX- Deficient Dogs. Science 262 (1993) 117.
Kaufman, R, Advances toward Gene Therapy for Hemophilia at the Millennium. Human Gene Therapy 10 (1999) 2091.
Kumar V and Eli Sercarz, Genetic vaccination: The advantages of going naked, Nature Medicine, Aug. 1996, 857-859, vol. 2 No. 8.
Lee, RC et al, Surfactant-induced sealing of electropermeabilized skeletal muscle membranes on vivo, PNAS, May 1992, 4524-4528, vol. 89.
Letvin, NL et al, Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination, PNAS, Aug. 1997, 9378-9383, vol. 94.
Levy, MY et al, Characterization of plasmid DNA transfer into mouse skeletal muscle: evaluation of uptake mechanism, expression and secretion of gene products into blood, Gene Therapy, 1996, 201-211, vol. 3.
Liu, MA et al, DNA Vaccines: A New Era in Vaccinology: Overview of DNA Vaccines, Annals of the New York Academy of Sciences, Nov. 27, 1995, 15-20, vol. 772.
Lozier, JN et al, Adenovirus-Mediated Expression of Human Coagulation Factor IX in the Rhesus Macaque Is Associated With Dose-Limiting Toxicity, Blood, Dec. 15, 1999, 3968-3975, vol. 94, No. 12.
Luke, CJ. et al, An OspA-Based DNA Vaccine Protects Mice against Infection with Borrelia burgdorferi, Journal of Infectious Diseases, 1997, 91-97, vol. 175.
Luo, D et al, Controlled DNA Delivery Systems, Pharmaceutical Research, 1999, 1300-1308, vol. 16 No. 8.
Mahato, R I et al, Biodistribution and Gene Expression of Lipid/Plasmid Complexes after Systemic Administration, Human Gene Therapy, Sep. 20, 1998, 2083-2099, vol. 9.
Kreiss P et al. Erythropoietin Secretion and Physiological Effect in Mouse after Intramuscular Plasmid DNA Electrotransfer. The Journal of Gene Medicine 1 (1999) 245.
Ljung RC et al. Prophylactic Infusion Regimens in the Management of Hemophilia. Thrombosis and Haemostasis 82 (1999) 525.
Maruyama, HI et al, Continuous Erythropoietin Delivery by Muscle-Targeted Gene Transfer Using in Vivo Electroporation, Human Gene Therapy, Feb. 10, 2000, 429-437, vol. 11.
Mathiesen, I, lectropermeabilization of skeletal muscle enhances gene transfer in vivo, Gene Therapy, 1996, 508-514, vol. 6.
Mir, L M et al, High-efficiency gene transfer into skeletal muscle mediated by electric pulses, PNAS, Apr. 1999, 4262-4267, vol. 96.
Mumper, R J.and Alain P. Rolland, Plasmid delivery to muscle: Recent advances in polymer delivery systems, Advanced Drug Delivery Reviews, 1998, 151-172, vol. 30.
Rizzuto, G et al, Efficient and regulated erythropoietin production by naked DNA
Fewell Jason
MacLaughlin Fiona
Nicol Francois
Rolland Alain
Smith Louis C.
Genetronics Biomedical Corporation
Schnizer Richard
Wong Cabello Lutsch Rutherford & Brucculeri LLP
LandOfFree
Nucleic acid formulations for gene delivery and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acid formulations for gene delivery and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid formulations for gene delivery and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3842774